Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Patients at High Risk of Cardiovascular Events, such as Heart Attack, Stroke and Cardiac DeathGlobeNewsWire • 10/17/19
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on StatinsGlobeNewsWire • 09/16/19
New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Management of Dyslipidaemias Incorporate Findings from the REDUCE-IT™ Cardiovascular Outcomes StudyGlobeNewsWire • 09/03/19
Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment ConferenceGlobeNewsWire • 08/28/19
Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Cholesterol ManagementGlobeNewsWire • 08/27/19
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech ConferenceGlobeNewsWire • 08/21/19